Eli Lilly’s New Obesity Drug Shows 20% Weight Loss
Eli Lilly is advancing its experimental obesity drug eloralintide to late-stage trials after promising mid-stage results. The highest dose showed 20.1% average weight loss at 48 weeks, positioning it as a potential competitor to GLP-1 drugs. The move intensifies the pharmaceutical battle in the lucr